Cellular Degradation Biology Center, Department of Biomedical Sciences, College of Medicine, Seoul National University, Seoul, Korea.
R&D Center, AUTOTAC Bio Inc ., Seoul, Korea.
Autophagy. 2022 Sep;18(9):2259-2262. doi: 10.1080/15548627.2022.2091338. Epub 2022 Jun 26.
Targeted protein degradation allows targeting undruggable proteins for therapeutic applications as well as eliminating proteins of interest for research purposes. While several types of degraders that harness the proteasome or the lysosome have been developed, a technology that simultaneously degrades targets and accelerates cellular autophagic flux remains unavailable. In this study, we developed a general chemical tool by which given intracellular proteins are targeted to macroautophagy for lysosomal degradation. This platform technology, termed AUTOTAC (AUTOphagy-TArgeting Chimera), employs bifunctional molecules composed of target-binding ligands (TBLs) linked to autophagy-targeting ligands (ATLs). Upon binding to targets via the TBL, the ATL binds the ZZ domain of the otherwise dormant autophagy receptor SQSTM1/p62 (sequestosome 1), which activates SQSTM1 associated with targets and sequesters them into oligomeric species for autophagic targeting and lysosomal degradation. AUTOTACs were used to degrade various oncoproteins or aggregation-prone proteins in neurodegeneration both and/or . We suggest that AUTOTAC provides a platform for selective proteolysis as a research tool and in drug development.
靶向蛋白降解允许针对不可成药的蛋白质进行治疗应用,以及消除研究目的感兴趣的蛋白质。虽然已经开发了几种利用蛋白酶体或溶酶体的降解剂,但同时降解靶标并加速细胞自噬流的技术仍然不可用。在这项研究中,我们开发了一种通用的化学工具,通过该工具,将给定的细胞内蛋白质靶向到溶酶体进行巨自噬降解。这种平台技术称为 AUTOTAC(自噬靶向嵌合体),它采用由靶向结合配体(TBL)与自噬靶向配体(ATL)连接而成的双功能分子。通过 TBL 与靶标结合后,ATL 与休眠自噬受体 SQSTM1/p62(自噬体 1)的 ZZ 结构域结合,该受体激活与靶标相关的 SQSTM1,并将其隔离成寡聚体,用于自噬靶向和溶酶体降解。AUTOTAC 用于降解神经退行性疾病中的各种致癌蛋白或易于聚集的蛋白。我们认为,AUTOTAC 为选择性蛋白水解提供了一个研究工具和药物开发的平台。